1. Edwards, J. E., Bodley, G. P., Bowden, R. A., Buchner, T., DePauw, B. E., Filler, S. G. et al.(1997). International conference for the development of a consensus on the management and prevention of severe candidal infections. Clinical Infectious Diseases25, 43–59.
2. Bartroli, J., Turmo, E., Algueró, M., Boncompte, M., Vericat, L., Conte, L., Ramis, J. et al. (1997). UR-9825: A new triazole derivative with potent broad-spectrum antifungal activity. In Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract E-67, p. 125. American Society for Microbiology, Washington, DC.
3. Bartroli, J., Turmo, E., Algueró, M., Boncompte, E., Vericat, M. L., Conte, L. et al. (1998). New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. Journal of Medical Chemistry41, 1869–82.
4. Vericat, M. L., Algueró, M., Merlos, M., Pérez, L. L., Araño, A. & Forn, J. (1997). UR-9825, a novel broad spectrum triazole for treatment of fungal infections: oral activity in systemic mycoses. In Final Programme and Abstract Book Trends in Invasive Fungal Infections 4., Barcelona, Spain, 1997.>Abstract P-94, p. 142. Imedex, The Netherlands.
5. National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Villanova, PA.